17/01/2017. ckit NRAS BRAF MEK ERK. ANTITUMOR IMMUNE RESPONSE PROLIFERATION
|
|
- Richard Wilkins
- 6 years ago
- Views:
Transcription
1 BRAF inhibitors: vemurafenib (Zelboraf ) dabrafenib (Tafinlar ) Universitair Ziekenhuis Gent MEK inhibitors: cobimetinib trametinib(mekinist ) selumetinib CUTANEOUS SIDE EFFECTS OF BRAF-INHIBITORS Lieve Brochez Hoogleraar Dermatologie Bestuurslid Immuno-oncologisch NetwerkGent (ION-Gent) BestuurslidCancer Research Institute Ghent (CRIG) Voorzitter Belgian Association of Dermato-Oncology (BADO) c-kit inhibitors: imatinib(glivec ) nilotinib(tasigna ) Dasatinib(Sprycel ) ckit NRAS BRAF MEK ERK Lieve.Brochez@ugent.be ANTITUMOR IMMUNE RESPONSE PROLIFERATION Anti CTLA4: ipilimumab (Yervoy ) Anti-PD1: nivolumab (Opdivo ) pembrolizumab (Keytruda ) Photosensitivity Facial erythema Cheilitis Xerosis Hyperkeratoses Keratosis follicularis Hand Foot Skin Reaction Other: mucosal (oral, vulvar), nipple Milia- Cystic lesions VerrucousPapilloma Keratoacanthoma SpinocellularCA Eruptive nevi second primary melanoma Radiodermitis Panniculitis Hair changes - alopecia * BoussemartL et al. Prospective study of cutaneousside-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol Feb 13. [Epubahead of print] **darocha Dias S. EurJ Cancer 2013 Adapted from BoussemartL. Ann Oncol
2 Photosensitivity mainly to UVA UVA penetrates clouds and glass UVA only slightly fluctuates during the day and with seasons DummerR. NEJM 2012 BoussemartL et al. Prospective study of cutaneousside-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol Feb 13. [Epubahead of print] ±1/3 pruritus R/: lower washing frequency, tepid water oily soaps nutritive cream 2
3 comparable to HFSR in multikinase inhibitors e.g. sorafenib and sunitinib mainly soles / palms esp. pressure points e.g. heel, MTP hyperkeratosis, erythema may be painful PREVENTION - cotton socks - adapted footwear - protect pressure points TREATMENT - preparations with ureum10-50% or salicylic acid 5-10% - topical corticoids in erythema - pedicure / podiatrist PREVENTIVE TREATMENT - emollient creams - ureum5-10% preparations mucosal: vulvar, oral nipple ±1/3 from 7-15w after start of R/ 70% 10% 20% nodular lesions with verrucous, hyperkeratotic aspect multiple > face, trunk 3
4 17/01/2017 Treatment: Verrucous papilloma: - cryo - curettage Kerato-acanthoma / SCC: - excision ; no interruption BRAFi Vemurafenib-related cutaneous side effects ameliorated by acitretin. J Drugs Dermatol. 2014; 13(5): 586 RISK FACTORS: Age 65j Increased prior sun exposure geographical variations PROGNOSIS: Low metastatic potential Spontaneous regression possible (after R/ stop) 4
5 MECHANISM: - Role HPV? Koilocyt-like cells in some lesions - Paradoxical stimulation MAPK pathway during BRAFi in case of BRAFwt and RAS mutation MEKi COMBI treatment : BRAFi + MEKi syngergistic antitumor activity decrease of proliferative skin lesions eruptive nevi in 10% darkening of the nevi changes of nevi BRIM 3: Phase 3 trial comparing RO in comparison with dacarbazine in previously untreated patients with metastastic melanoma vemurafenib(n=5) dacarbazine(n=6) Total body examination + dermoscopy 6 atypical lesions excised (n=4) No lesions excised 5 melanomas (BRAF wt) 5
6 Stop BRAFi5 half lives before and after RT Imke Satzger et al. JCO 2013;31:e220-e222 Hair loss(8-36%) / thinning Changes in structure (curly hair) Changes in color (greying) Friable nails Colorchanges of the nails R/ NSAID systemic corticoids 6
7 CUTANEOUS SIDE EFFECTS OF BRAF-INHIBITORS CONCLUSIONS CUTANEOUS SIDE EFFECTS: -FREQUENT -PREDOMINANT -AFFECTING QUALITY OF LIFE PATIENT EDUCATION e.g. photosensitivity e.g. prevention of HFSR BRAF inhibitors: vemurafenib (Zelboraf ) dabrafenib (Tafinlar ) DERMATOLOGICAL FOLLOW-UP - before start - after 6-10w - photographic documentation Induction of: KA, SCC Melanoma (?) Other malignancies?? Repercussions for use in the adjuvant setting at least in monotherapy BRAF inhibitors: vemurafenib (Zelboraf ) dabrafenib (Tafinlar ) 7
Cutaneous reactions to targeted therapies. Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017
Cutaneous reactions to targeted therapies Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017 Disclosures I have no relevant disclosures Papulopustular Eruption
More informationAcute drug reactions associated with the novel targeted therapies used in treating skin cancer
Acute drug reactions associated with the novel targeted therapies used in treating skin cancer Dr Rishika Sinha Consultant Dermatologist Chelsea & Westminster Hospital NHS Foundation Trust West Middlesex
More informationBRAF Inhibition in Melanoma
BRAF Inhibition in Melanoma New York City, Mar 22-23, 2013 Bartosz Chmielowski, MD, PhD Assistant Clinical Professor University of California Los Angeles Disclosures Speaker Bureau: BMS, Genentech, Prometheus
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More informationWhat You Need to Know about Advanced Melanoma Therapies Targeted Approaches
2018 AAD Annual Meeting, San Diego, CA What You Need to Know about Advanced Melanoma Therapies Targeted Approaches Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion & Melanoma
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationBlack is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)
Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Provincial Cancer Care Conference 2018 Ralph P.W. Wong MD FRCPC St Boniface Site Director
More informationUpdate on Targeted Therapy in Melanoma
Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1
More informationProspective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
670368CMSXXX10.1177/1203475416670368Journal of Cutaneous Medicine and SurgeryLacroix and Wang research-article2016 Original Article Prospective Case Series of Cutaneous Adverse Effects Associated With
More informationNormal RAS-RAF (MAPK) pathway signaling
BRAF-Mutations in Melanomas L. Mazzucchelli Istituto Cantonale di Patologia, Locarno 77. Annual Meeting Swiss Society of Pathology, Lucerne 2011 Sponsored by Roche Pharma Switzerland Melanoma has increased
More informationDermatologists & Oncologists: Two important reasons we are getting closer. Ioanna Panoutsopoulou, MD. GAMC June 1 st 2016
Dermatologists & Oncologists: Two important reasons we are getting closer Ioanna Panoutsopoulou, MD GAMC June 1 st 2016 Points of presentation Cutaneous adverse events from: Epidermal Growth Factor Receptor
More informationAdvances in Melanoma
Advances in Melanoma The Blue, the Black and the Ugly 1 Outline History of Melanoma Why be concerned? Skin cancer updates What s old? What s new (and why are Skin Tumor Group med oncs excited again)? What
More informationMultikinase inhibitors: Multikinase inhibitors: Regorafenib skin toxicity. Cutaneous side effects of multikinase-inhibitors and their management
TARGETED THERAPIES AND THEIR CUTANEOUS TOXICITIES Brussels, 14/1/2017 Cutaneous side effects of multikinase-inhibitors and their management Siegfried Segaert Dermatology Dept. Uinversity Hospital Leuven
More informationTargeted Therapies 5/21/2018. Iatrogenic Dermatopathology: When Therapy Goes Wrong
Iatrogenic Dermatopathology: When Therapy Goes Wrong Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu I do not have any relevant relationships with industry Targeted
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationThe Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma
The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma Reinhard Dummer, 1 Keith Flaherty, 2 Richard Kefford, 3 Paolo A. Ascierto, 4 Laure Moutouh-de Parseval,
More informationSkin cancer is the most common
Section Editors: Christopher J. Campen and Beth Eaby-Sandy Vemurafenib: First-in-Class BRAF- Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma LINDSAY SHELLEDY, PharmD, and DANIELLE
More informationSkin Side Effects U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A
Skin Side Effects Christiane Thallinger, M D U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A Targets Substances 1 Multi Kinase Inhibitors
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationCorporate Medical Policy
Corporate Medical Policy BRAF Gene Variant Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_variant_testing_to_select_melanoma_or_glioma_patients_for_targeted_
More informationReview Article Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
Dermatology Research and Practice Volume 2016, Article ID 5361569, 6 pages http://dx.doi.org/10.1155/2016/5361569 Review Article Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of
More informationEmerging Trends & Strategies in the Treatment & Management of Metastatic Melanoma. Evan J. Lipson, MD
Emerging Trends & Strategies in the Treatment & Management of Metastatic Melanoma Evan J. Lipson, MD Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center April 25, 2014
More informationBest Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationMelanoma- Fighting the Dark Side
Melanoma- Fighting the Dark Side Anna C. Pavlick, BSN, MSc, DO, MBA Professor of Medicine and Dermatology Director, NYU Melanoma Program Director, NYU Clinical Trials Office NYU Perlmutter Cancer Center
More informationUpdate on Melanoma Treatment. Tara C Mitchell, MD
Update on Melanoma Treatment Tara C Mitchell, MD Overview Immune therapy update Targeted therapy update New concepts in treating melanoma What is the immune system? A complex network of protective cells
More informationModern therapy in oncology Metastatic melanoma
Modern therapy in oncology Metastatic melanoma Anna Buda-Nowak Oncology Department; University Hospital in Cracow Melanoma Malignant skin neoplasm derived from neuroectodermal melanomatous cells. The incidence:
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic BRAF V600 mutation-positive melanoma mutation-positive melanoma
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationCorporate Medical Policy
Corporate Medical Policy BRAF Gene Mutation Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_mutation_testing_to_select_melanoma_or_glioma_patients_for_targeted_
More informationMelanoma: Early Detection and Therapeutic Progress
Melanoma: Early Detection and Therapeutic Progress David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Surgery Thanks to my collaborators, mentors and patients May 19, 2017 Disclosures:
More informationBRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy
Medical Policy Manual Genetic Testing, Policy No. 41 BRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy Next Review: August 2019 Last Review: July 2018 Effective: August 1,
More informationMEK/BRAF inhibitors and the implications on patients and health care providers
MEK/BRAF inhibitors and the implications on patients and health care providers Tara McKeown NP Paediatric Neuro Oncology Hospital for Sick Children Adjunct Lecturer, Lawrence S. Bloomberg, Faculty of Nursing,
More informationLocally Advanced and Metastatic Melanoma. Relevant disclosures 6/23/2018. What is the median survival of metastatic melanoma? Abel D.
Locally Advanced and Metastatic Melanoma Abel D. Jarell, MD, FAAD Adjunct Dartmouth School of Medicine, Hanover, NH Northeast Dermatology Associates, Portsmouth, NH Relevant disclosures What is the median
More informationCutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.
Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma
More informationErdheim-Chester disease and Skin issues
Erdheim-Chester disease and Skin issues STÉPHANE BARETE, MD, PHD UNIT OF DERMATOLOGY PITIÉ -SALPÊTRIÈRE HOSPITAL PARIS stephane.barete@aphp.fr Introduction Erdheim-Chester (ECD) is an orphan disease included
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationAperTO - Archivio Istituzionale Open Access dell'università di Torino
AperTO - Archivio Istituzionale Open Access dell'università di Torino Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. This is
More informationMelanoma 10/12/18 Justin J. Baker, M.D.
Objectives Review Incidence Risk Factors for Development Detection 10/12/18 Justin J. Baker, M.D. Treatment of Surgery Medicine Radiation What is Incidence Cancer of Melanocytes Melanocytes are normal
More informationMetastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds
Metastatic Melanoma Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds Case Presentation 77 year old male with previous history of scalp melanoma and thyroid
More informationLiving Beyond Cancer Skin Cancer Detection and Prevention
Living Beyond Cancer Skin Cancer Detection and Prevention Cutaneous Skin Cancers Identification Diagnosis Treatment options Prevention What is the most common cancer in people? What is the most common
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationSignificance. Outline and Objectives. S007 Systemic Therapies for Medical Oncology
S007 Systemic Therapies for Medical Oncology Anisha B. Patel, M.D. Assistant Professor, Dermatology UT MD Anderson Cancer Center UT Health Science Center Houston Safety considerations Outline and Objectives
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More informationBRAF Inhibitors in Metastatic disease. Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia
Inhibitors in Metastatic disease Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia Disclosures Research Support Pfizer & Cellgene Consultant Provectus Mortality from Melanoma
More informationSkin toxicities from cancer treatments
Outline Skin toxicities from cancer treatments Resident Power Hour Cecilia Larocca, MD Centers for Melanoma and Cutaneous Oncology Brigham and Women s Hospital/Dana- Farber Cancer Institute Harvard Medical
More informationvemurafenib 240mg film-coated tablet (Zelboraf ) SMC No. (792/12) Roche Products Ltd.
Resubmission vemurafenib 240mg film-coated tablet (Zelboraf ) SMC No. (792/12) Roche Products Ltd. 08 November 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationRare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham
Rare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham Classifying melanoma Melanoma (site of origin, thickness,
More informationINIBITORE di BRAF nel MELANOMA
INIBITORE di BRAF nel MELANOMA Paola Agnese Cassandrini Negrar,29 novembre 2016 BRAF is a serine/threonine protein kinasi encoded on chromosome 7q34 that activates the MAP kinase/erksegnaling pathway
More informationBRAF Gene Variant Testing To Select Melanoma or Glioma Patients for Targeted Therapy
BRAF Gene Variant Testing To Select Melanoma or Glioma Patients for Targeted Therapy Policy Number: 2.04.77 Last Review: 12/2018 Origination: 4/2013 Next Review: 12/2019 Policy Blue Cross and Blue Shield
More information1. Opdivo + Ipilumimab is now the first line therapy for metastatic melanoma.
Melanoma UpToDate: Introduction: Risk Factors: 1. Opdivo + Ipilumimab is now the first line therapy for metastatic melanoma. Median age = 50 yrs Incidence is rising - Sun exposure: UVB (290-320nm) > UVA
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
National Institute for Health and Care Excellence Single Technology Appraisal (STA) Nivolumab for treating advanced (unresectable or metastatic) melanoma At the scoping consultation stage, the scopes for
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationMAPK Pathway. CGH Next Generation Sequencing. Molecular Tools in Care of Patients with Pigmented Lesions 7/20/2017
Molecular Tools in Care of Patients with Pigmented Lesions Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Tammie Ferringer,
More informationA New Era In Treatment Of Malignant Melanoma: Biological therapies
A New Era In Treatment Of Malignant Melanoma: Biological therapies Anila Kirt, Jingjun Zhao Department of Dermatology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China A
More informationToxicity of Systemic Melanoma Therapies. Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney
Toxicity of Systemic Melanoma Therapies Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney Disclosures Advisory Board Novartis, BMS, Sanofi, Pfizer Travel support
More informationBenign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc
1 Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc Benign lesions Seborrheic Keratoses: Warty, stuck-on Genetics and birthdays Can start in late
More informationYervoy. Yervoy (ipilimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 5 Last Review Date: September 15, 2017 Yervoy Description Yervoy (ipilimumab)
More informationSystemic implications of Melanoma. Melanoma 2/4/2018. Cancer USA Epidemiology: Incidence and Mortality. Skin Cancer USA
Systemic implications of Melanoma Darrell S. Rigel, MD MS Clinical Professor of Dermatology New York University Medical Center New York, New York DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Darrell
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More informationWhat's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationEvolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures
Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory
More informationAdvanced Skin Cancer and Melanoma
treatment Update: Advanced Skin Cancer and Melanoma CancerCare Connect Booklet Series www.cancercare.org The CancerCare Connect Booklet Series offers up-to-date, easy-to-read information on the latest
More informationA View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
More informationNew treatments in melanoma
New treatments in melanoma Paolo A. Ascierto, MD Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationDisclosures. Melanoma and Non melanoma Skin Cancer: What You Need to Know. I have no conflicts of interest to disclose
Disclosures Melanoma and Non melanoma Skin Cancer: What You Need to Know I have no conflicts of interest to disclose Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department
More informationField vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM
Dilemmas and Challenges in Skin Cancer Therapies and Management Field vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM Roger I. Ceilley, M.D. Clinical Professor of Dermatology The University of Iowa
More informationBRAF Gene Mutation Testing To Select Melanoma or Glioma Patients for Targeted Therapy
BRAF Gene Mutation Testing To Select Melanoma or Glioma Patients for Targeted Therapy Policy Number: 2.04.77 Last Review: 12/2017 Origination: 4/2013 Next Review: 12/2018 Policy Blue Cross and Blue Shield
More informationThe information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information
The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: October 18, 2017 Report Length: 20 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL BRAF Targeted Therapy after Immunotherapy for Patients with Metastatic Melanoma: A Review of Clinical Effectiveness Service Line: Rapid Response
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationThe University of Texas MD Anderson Cancer. and Translational and Molecular Pathology. Translational Research Program The Alliance for Clinical Trials
Cutaneous toxicities to oncologic therapies and Interpretation of Immunohistochemistry Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology, Section of Dermatopathology and Translational
More informationNovel Therapies in Melanoma the Immunotherapy Approach
2018 AAD Annual Meeting, San Diego, CA Novel Therapies in Melanoma the Immunotherapy Approach Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion & Melanoma Program Physician
More informationDisclosure Information. Lecture Outline. Lecture Outline. Introduction. Molecular Pathology of Cutaneous Melanoma. Nothing to disclose
Molecular Pathology of Cutaneous Melanoma Disclosure Information Nothing to disclose Jonathan L. Curry, MD Assistant Professor of Pathology and Dermatology University of Texas-MD Anderson Cancer Center
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationInitial Results from an Open-label, Doseescalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600 mutant Advanced Melanoma
Initial Results from an Open-label, Doseescalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600 mutant Advanced Melanoma Reinhard Dummer, 1 Caroline Robert, 2 Marta Nyakas, 3 Grant McArthur,
More informationDabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Dabrafenib for treating unresectable or metastatic BRAF V600 Issued: October 2014 guidance.nice.org.uk/ta321 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More informationBRAF pathway. Sun Young Kim. Division of Medical Oncology Center for Colorectal Cancer National Cancer Center
BRAF pathway Sun Young Kim Division of Medical Oncology Center for Colorectal Cancer National Cancer Center Contents BRAF inhibitor in advanced melanoma Paradoxical MAPK pathway activation by BRAF inhibitor
More informationCADTH TECHNOLOGY REVIEW Metastatic Melanoma Gap Analysis
CADTH TECHNOLOGY REVIEW Metastatic Melanoma Gap Analysis Service Line: Technology Review Issue Number: 9 Publication Date: June 2018 Report Length: 66 Pages Authors: Kimberly Castellano, Susan Mirabi,
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationTAFINLAR. Public Summary of the EU Risk Management Plan (RMP) v9.1 for Tafinlar (dabrafenib)
Drug Regulatory Affairs TAFINLAR 50 and 75 mg hard capsules Public Summary of the EU Risk Management Plan (RMP) v9.1 for Tafinlar (dabrafenib) Document version: 9.1 Document status: Final Document Date:
More informationPei-han Kao, 高珮菡 Department of Dermatology, Chang Gang Memorial Hospital 林口長庚醫院皮膚科
Pei-han Kao, 高珮菡 Department of Dermatology, Chang Gang Memorial Hospital 林口長庚醫院皮膚科 Clear evidence that rash presence/severity correlates with response May compromise quality of life and require to minimize
More informationNieuwe behandelingsmethodes in de oncologie
Nieuwe behandelingsmethodes in de oncologie Vibeke Kruse MD PhD Medical Oncologist Clinical Pharmacologist Department of Medical Oncology UZ Gent 20 Juni 2017 Outline 1) Introduction 2) Systemic therapy
More informationInvolvement of TLR4/STAT3 signaling in the antimelanoma effects of atractylenolide II. Fu Xiuqiong
Involvement of TLR4/STAT3 signaling in the antimelanoma effects of atractylenolide II Fu Xiuqiong Melanoma fact Skin cancers Skin cancer deaths 2.3% 75% Melanoma Non-melanoma skin cancers ----American
More informationThe Biology and Therapeutic Approach to BRAF-Mutant Cutaneous Melanoma
The Biology and Therapeutic Approach to BRAF-Mutant Cutaneous Melanoma Kevin Wood, MD, and Jason Luke, MD, FACP Abstract Knowledge regarding the biology and therapeutic value of BRAF mutations in melanoma
More informationSubject: Cobimetinib (Cotellic ) Tablet
09-J2000-53 Original Effective Date: 03/15/16 Reviewed: 11/14/18 Revised: 12/15/18 Subject: Cobimetinib (Cotellic ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationBRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma
QUALITY OF LIFE IN ONCOLOGY Review article BRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma Maksymilian Kruczała, Aleksandra Grela-Wojewoda, Marek Ziobro Clinic of Systemic and Metastatic
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More information